Heat-labile enterotoxin iia, a platform to deliver heterologous proteins into neurons

mBio

Volumn 6, Issue 4, 2015, Pages

  Chen, Chen ^a   Przedpelski, Amanda ^a   Tepp, William H ^b   Pellett, Sabine ^b   Johnson, Eric A ^b   Barbieri, Joseph T ^a  

^a MEDICAL COLLEGE OF WISCONSIN   (United States)

^b UNIVERSITY OF WISCONSIN MADISON   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ANTIBODY; BETA LACTAMASE; BOTULINUM NEUROTOXIN D; BOTULINUM TOXIN; BOTULINUM TOXIN A; BREFELDIN A; ENTEROTOXIN; GANGLIOSIDE; GANGLIOSIDE GD 1B; HEAT LABILE ENTEROTOXIN IIA; SYNAPTOSOMAL ASSOCIATED PROTEIN 25; UNCLASSIFIED DRUG; VHH B8 LTIIA ANTIBODY; BACTERIAL TOXIN; CARRIER PROTEIN; ESCHERICHIA COLI PROTEIN; HEAT-LABILE ENTEROTOXIN, E COLI; HYBRID PROTEIN; SINGLE CHAIN FRAGMENT VARIABLE ANTIBODY;

ANIMAL CELL; ARTICLE; CHEMOSENSITIVITY; CYTOSOL; DRUG DELIVERY SYSTEM; GENETIC ENGINEERING; GOLGI COMPLEX; HUMAN; HUMAN CELL; NERVE CELL; NONHUMAN; PRIORITY JOURNAL; PROTEIN CLEAVAGE; PROTEIN TRANSPORT; RAT; SYNAPSE VESICLE; TOXIN STRUCTURE; CELL LINE; ENDOCYTOSIS; GENETICS; METABOLISM; PHYSIOLOGY;

BACTERIAL TOXINS; BETA-LACTAMASES; CARRIER PROTEINS; CELL LINE; ENDOCYTOSIS; ENTEROTOXINS; ESCHERICHIA COLI PROTEINS; HUMANS; NEURONS; PROTEIN TRANSPORT; RECOMBINANT FUSION PROTEINS; SINGLE-CHAIN ANTIBODIES;

EID: 84940833015     PISSN: 21612129     EISSN: 21507511     Source Type: Journal    
DOI: 10.1128/mBio.00734-15     Document Type: Article

References (45)

1. Pálffy R, Gardlík R, Hodosy J, Behuliak M, Resko P, Radvánský J, Celec P. 2006. Bacteria in gene therapy: bactofection versus alternative gene therapy. Gene Ther 13:101–105. http://dx.doi.org/10.1038/sj.gt.3302635.
2. Gardlík R, Pálffy R, Hodosy J, Lukács J, Turna J, Celec P. 2005. Vectors and delivery systems in gene therapy. Med Sci Monit 11:RA110–RA121.
3. Goeddel DV, Kleid DG, Bolivar F, Heyneker HL, Yansura DG, Crea R, Hirose T, Kraszewski A, Itakura K, Riggs AD. 1979. Expression in Escherichia coli of chemically synthesized genes for human insulin. Proc Natl Acad Sci USA 76:106–110. http://dx.doi.org/10.1073/pnas.76.1.106.
4. Walsh G. 2010. Biopharmaceutical benchmarks 2010. Nat Biotechnol 28:917–924. http://dx.doi.org/10.1038/nbt0910-917.
5. Heilmann C, von Samson P, Schlegel K, Attmann T, von Specht BU, Beyersdorf F, Lutter G. 2002. Comparison of protein with DNA therapy for chronic myocardial ischemia using fibroblast growth factor-2. Eur J Cardiothorac Surg 22:957–964. http://dx.doi.org/10.1016/S1010-7940(02)00577-8.
6. Cui M, Wan Y, Anderson DG, Shen FH, Leo BM, Laurencin CT, Balian G, Li X. 2008. Mouse growth and differentiation factor-5 protein and DNA therapy potentiates intervertebral disc cell aggregation and chondrogenic gene expression. Spine J 8:287–295. http://dx.doi.org/10.1016/j.spinee.2007.05.012.
7. Akamatsu Y, Murphy JC, Nolan KF, Thomas P, Kreitman RJ, Leung SO, Junghans RP. 1998. A single-chain immunotoxin against carcinoembryonic antigen that suppresses growth of colorectal carcinoma cells. Clin Cancer Res 4:2825–2832.
8. Bradley KA, Mogridge J, Mourez M, Collier RJ, Young JA. 2001. Identification of the cellular receptor for anthrax toxin. Nature 414: 225–229. http://dx.doi.org/10.1038/n35101999.
9. Varughese M, Chi A, Teixeira AV, Nicholls PJ, Keith JM, Leppla SH. 1998. Internalization of a Bacillus anthracis protective antigen-c-Myc fusion protein mediated by cell surface anti-c-Myc antibodies. Mol Med 4:87–95.
10. Trinh KR, Vasuthasawat A, Steward KK, Yamada RE, Timmerman JM, Morrison SL. 2013. Anti-CD20-interferon-beta fusion protein therapy of murine B-cell lymphomas. J Immunother 36:305–318. http://dx.doi.org/10.1097/CJI.0b013e3182993eb9.
11. Olafsen T, Elgqvist J, Wu AM. 2011. Protein targeting constructs in alpha therapy. Curr Radiopharm 4:197–213. http://dx.doi.org/10.2174/1874471011104030197.
12. Pastan I, Hassan R, Fitzgerald DJ, Kreitman RJ. 2006. Immunotoxin therapy of cancer. Nat Rev Cancer 6:559–565. http://dx.doi.org/10.1038/nrc1891.
13. Beddoe T, Paton AW, Le Nours J, Rossjohn J, Paton JC. 2010. Structure, biological functions and applications of the AB5 toxins. Trends Biochem Sci 35:411–418. http://dx.doi.org/10.1016/j.tibs.2010.02.003.
14. Sanchez J, Holmgren J. 2011. Cholera toxin—a foe and a friend. Indian J Med Res 133:153–163.
15. McKenzie SJ, Halsey JF. 1984. Cholera toxin B subunit as a carrier protein to stimulate a mucosal immune response. J Immunol 133:1818–1824.
16. Bharati K, Ganguly NK. 2011. Cholera toxin: a paradigm of a multifunctional protein. Indian J Med Res 133:179–187.
17. Lewis DJ, Huo Z, Barnett S, Kromann I, Giemza R, Galiza E, Woodrow M, Thierry-Carstensen B, Andersen P, Novicki D, Del Giudice G, Rappuoli R. 2009. Transient facial nerve paralysis (Bell’s palsy) following intranasal delivery of a genetically detoxified mutant of Escherichia coli heat labile toxin. PLoS One 4:e6999. http://dx.doi.org/10.1371/journal.pone.0006999.
18. Hajishengallis G, Connell TD. 2013. Type II heat-labile enterotoxins: structure, function, and immunomodulatory properties. Vet Immunol Immunopathol 152:68–77. http://dx.doi.org/10.1016/j.vetimm.2012.09.034.
19. Greene CJ, Chadwick CM, Mandell LM, Hu JC, O’Hara JM, Brey RN, Mantis NJ, Connell TD. 2013. LT-IIb(T13I), a non-toxic type II heatlabile enterotoxin, augments the capacity of a ricin toxin subunit vaccine to evoke neutralizing antibodies and protective immunity. PLoS One 8:e69678. http://dx.doi.org/10.1371/journal.pone.0069678.
20. Schwarz A, Futerman AH. 1996. The localization of gangliosides in neurons of the central nervous system: the use of anti-ganglioside antibodies. Biochim Biophys Acta 1286:247–267. http://dx.doi.org/10.1016/S0304-4157(96)00011-1.
21. Fukuta S, Magnani JL, Twiddy EM, Holmes RK, Ginsburg V. 1988. Comparison of the carbohydrate-binding specificities of cholera toxin and Escherichia coli heat-labile enterotoxins Lth-I, LT-IIa, and LT-IIb. Infect Immun 56:1748–1753.
22. Marketon MM, DePaolo RW, DeBord KL, Jabri B, Schneewind O. 2005. Plague bacteria target immune cells during infection. Science 309: 1739–1741. http://dx.doi.org/10.1126/science.1114580.
23. Zlokarnik G, Negulescu PA, Knapp TE, Mere L, Burres N, Feng L, Whitney M, Roemer K, Tsien RY. 1998. Quantitation of transcription and clonal selection of single living cells with beta-lactamase as reporter. Science 279:84–88. http://dx.doi.org/10.1126/science.279.5347.84.
24. Blum FC, Przedpelski A, Tepp WH, Johnson EA, Barbieri JT. 2014. Entry of a recombinant, full-length, atoxic tetanus neurotoxin into Neuro-2a cells. Infect Immun 82:873–881. http://dx.doi.org/10.1128/IAI.01539-13.
25. Lencer WI, Hirst TR, Holmes RK. 1999. Membrane traffic and the cellular uptake of cholera toxin. Biochim Biophys Acta 1450:177–190. http://dx.doi.org/10.1016/S0167-4889(99)00070-1.
26. Donta ST, Beristain S, Tomicic TK. 1993. Inhibition of heat-labile cholera and Escherichia coli enterotoxins by brefeldin A. Infect Immun 61: 3282–3286.
27. Tremblay JM, Kuo CL, Abeijon C, Sepulveda J, Oyler G, Hu X, Jin MM, Shoemaker CB. 2010. Camelid single domain antibodies (VHHs) as neuronal cell intrabody binding agents and inhibitors of Clostridium botulinum neurotoxin (BoNT) proteases. Toxicon 56:990–998. http://dx.doi.org/10.1016/j.toxicon.2010.07.003.
28. Liang S, Hosur KB, Lu S, Nawar HF, Weber BR, Tapping RI, Connell TD, Hajishengallis G. 2009. Mapping of a microbial protein domain involved in binding and activation of the TLR2/TLR1 heterodimer. J Immunol 182:2978–2985. http://dx.doi.org/10.4049/jimmunol.0803737.
29. Van den Akker F, Sarfaty S, Twiddy EM, Connell TD, Holmes RK, Hol WG. 1996. Crystal structure of a new heat-labile enterotoxin, LT-IIb. Structure 4:665–678. http://dx.doi.org/10.1016/S0969-2126(96)00073-1.
30. Whitemarsh RC, Tepp WH, Johnson EA, Pellett S. 2014. Persistence of botulinum neurotoxin a subtypes 1–5 in primary rat spinal cord cells. PLoS One 9:e90252. http://dx.doi.org/10.1371/journal.pone.0090252.
31. Mukherjee J, Tremblay JM, Leysath CE, Ofori K, Baldwin K, Feng X, Bedenice D, Webb RP, Wright PM, Smith LA, Tzipori S, Shoemaker CB. 2012. A novel strategy for development of recombinant antitoxin therapeutics tested in a mouse botulism model. PLoS One 7:e29941. http://dx.doi.org/10.1371/journal.pone.0029941.
32. Dong J, Thompson AA, Fan Y, Lou J, Conrad F, Ho M, Pires-Alves M, Wilson BA, Stevens RC, Marks JD. 2010. A single-domain llama antibody potently inhibits the enzymatic activity of botulinum neurotoxin by binding to the non-catalytic alpha-exosite binding region. J Mol Biol 397: 1106–1118. http://dx.doi.org/10.1016/j.jmb.2010.01.070.
33. Zhang P, Ray R, Singh BR, Ray P. 2013. Mastoparan-7 rescues botulinum toxin-A poisoned neurons in a mouse spinal cord cell culture model. Toxicon 76:37–43. http://dx.doi.org/10.1016/j.toxicon.2013.09.002.
34. Zhang P, Ray R, Singh BR, Li D, Adler M, Ray P. 2009. An efficient drug delivery vehicle for botulism countermeasure. BMC Pharmacol 9:12. http://dx.doi.org/10.1186/1471-2210-9-12.
35. Edupuganti OP, Ovsepian SV, Wang J, Zurawski TH, Schmidt JJ, Smith L, Lawrence GW, Dolly JO. 2012. Targeted delivery into motor nerve terminals of inhibitors for SNARE-cleaving proteases via liposomes coupled to an atoxic botulinum neurotoxin. FEBS J 279:2555–2567. http://dx.doi.org/10.1111/j.1742-4658.2012.08638.x.
36. Jin R, Rummel A, Binz T, Brunger AT. 2006. Botulinum neurotoxin B recognizes its protein receptor with high affinity and specificity. Nature 444:1092–1095. http://dx.doi.org/10.1038/nature05387.
37. Chai Q, Arndt JW, Dong M, Tepp WH, Johnson EA, Chapman ER, Stevens RC. 2006. Structural basis of cell surface receptor recognition by botulinum neurotoxin B. Nature 444:1096–1100. http://dx.doi.org/10.1038/nature05411.
38. Dong M, Yeh F, Tepp WH, Dean C, Johnson EA, Janz R, Chapman ER. 2006. SV2 is the protein receptor for botulinum neurotoxin A. Science 312:592–596. http://dx.doi.org/10.1126/science.1123654.
39. Kuo CL, Oyler GA, Shoemaker CB. 2011. Accelerated neuronal cell recovery from botulinum neurotoxin intoxication by targeted ubiquitination. PLoS One 6: e20352. http://dx.doi.org/10.1371/journal.pone.0020352.
40. Mukherjee J, Dmitriev I, Debatis M, Tremblay JM, Beamer G, Kashentseva EA, Curiel DT, Shoemaker CB. 2014. Prolonged prophylactic protection from botulism with a single adenovirus treatment promoting serum expression of a VHH-based antitoxin protein. PLoS One 9:e106422. http://dx.doi.org/10.1371/journal.pone.0106422.
41. Lansbury PT, Lashuel HA. 2006. A century-old debate on protein aggregation and neurodegeneration enters the clinic. Nature 443:774–779. http://dx.doi.org/10.1038/nature05290.
42. Mueller NH, Gilden DH, Cohrs RJ, Mahalingam R, Nagel MA. 2008. Varicella zoster virus infection: clinical features, molecular pathogenesis of disease, and latency. Neurol Clin 26:675–697. http://dx.doi.org/10.1016/j.ncl.2008.03.011.
43. Blum FC, Chen C, Kroken AR, Barbieri JT. 2012. Tetanus toxin and botulinum toxin a utilize unique mechanisms to enter neurons of the central nervous system. Infect Immun 80:1662–1669. http://dx.doi.org/10.1128/IAI.00057-12.
44. Prabakaran S, Tepp W, DasGupta BR. 2001. Botulinum neurotoxin types B and E: purification, limited proteolysis by endoproteinase Glu-C and pepsin, and comparison of their identified cleaved sites relative to the three-dimensional structure of type A neurotoxin. Toxicon 39: 1515–1531. http://dx.doi.org/10.1016/S0041-0101(01)00124-6.
45. Malizio CJ, Goodnough MC, Johnson EA. 2000. Purification of Clostridium botulinum type A neurotoxin. Methods Mol Biol 145:27–39. http://dx.doi.org/10.1385/1-59259-052-7:27.